HUTCHMED (China) Limited (HCM)
| Market Cap | 1.54B |
| Revenue (ttm) | 356.13M |
| Net Income (ttm) | -194.65M |
| Shares Out | 172.91M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 973,551 |
| Open | 10.27 |
| Previous Close | 10.50 |
| Day's Range | 8.78 - 10.67 |
| 52-Week Range | 8.78 - 43.94 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 32.36 (+263.2%) |
| Earnings Date | Mar 3, 2022 |
About HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointesti...
Financial Performance
In 2021, HCM's revenue was $356.13 million, an increase of 56.21% compared to the previous year's $227.98 million. Losses were -$194.65 million, 54.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for HCM stock is "Buy." The 12-month stock price forecast is 32.36, which is an increase of 263.19% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HUTCHMED (China) Limited - HCM
New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors ...
HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendoc...
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT
7 Biotech Stocks to Buy With Key Catalysts for April
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belon...
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting sta...
Update on Status under Holding Foreign Companies Accountable Act
HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its statu...
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.
Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting risk
Shares of Chinese companies flagged for possible delisting in the U.S. slid in Hong Kong and Shanghai trading Friday, a move that analysts said highlighted geopolitical tensions but would have little im...
Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.
Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. The post Which Chinese Stocks Could Get Delisted?
Why Chinese Stocks Are Falling Apart; Two Chinese Stocks to Dump Immediately
Even China's most prominent companies were not immune to the sharp falls.
Why Tesla Stock Slumped With Li Auto, Tencent Music, and Hutchmed
The risks of investing in Chinese stocks are growing.
What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today
Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM), have been flagged by the SEC for failing to comply w...
MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listings
Shares of many U.S.-listed Chinese stocks tumbled Thursday after the Securities and Exchange Commission put out an update about foreign companies using accounting firms or branches that cannot be adequa...
These Chinese stocks are down sharply on Thursday. Here's what could be behind the decline
A 2020 law called the Holding Foreign Companies Accountable Act may be behind the sharp decline in a handful of U.S-traded Chinese stocks.
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase II...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from A...
HUTCHMED announces retirement of CEO and appointment of new CEO
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces:
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE ® growth and the 2021 launches of SULANDA ® and ORPATHYS ® ;
HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
First homegrown innovative medicine approved in Macau based on China clinical data First homegrown innovative medicine approved in Macau based on China clinical data
HUTCHMED to Announce 2021 Final Results
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year...
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid T...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/I...
HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in Chi...
HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing in...
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytop...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation o...
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lym...
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED —
HUTCHMED Included in FTSE Russell Indexes
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE ...
HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studie...